(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 5% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 10.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
10x Genomics's revenue in 2025 is $610,785,000.On average, 7 Wall Street analysts forecast TXG's revenue for 2025 to be $74,598,252,522, with the lowest TXG revenue forecast at $73,329,737,827, and the highest TXG revenue forecast at $75,701,782,033. On average, 8 Wall Street analysts forecast TXG's revenue for 2026 to be $82,073,952,553, with the lowest TXG revenue forecast at $79,488,002,427, and the highest TXG revenue forecast at $84,066,616,448.
In 2027, TXG is forecast to generate $90,585,671,479 in revenue, with the lowest revenue forecast at $83,462,323,052 and the highest revenue forecast at $93,845,871,655.